Articles tagged with Cancer Medication
Researchers at Stanford University School of Medicine have identified two new proteins that make up the telomerase complex, providing new targets for cancer treatments. The discovery could lead to the development of drugs that block telomerase and slow or stop cancer cell growth.
Researchers at IUPUI have created the first 3-D image of how bleomycin targets and binds to DNA. This breakthrough study may lead to improved chemotherapy drugs for various cancers.
A new feedback control scheme can search for the most effective drug combinations to treat various conditions, including cancers and infections. The discovery holds promise for facilitating new clinical drug-cocktail trials and optimizing combination therapies while reducing side effects.
Researchers found that dopamine can block the growth of new blood vessels in cancer cells by binding to a specific receptor on endothelial progenitor cells. This could lead to a potential treatment for cancer patients, as it slows down cancer progression and reduces tumor growth.
Researchers have discovered that an enzyme called MMP-2 is necessary for ovarian cancer to attach itself to new sites, and that blocking its production can slow the spread of the disease. In a mouse study, early treatment with an MMP-2 inhibitor reduced tumor growth by 68% and nearly doubled survival time.
A new study has discovered that specific pre-existing IgE antibodies are the primary cause of severe allergic reactions to cancer drug cetuximab. The research found these antibodies were more prevalent in certain regions of the US, including Tennessee, Arkansas, and North Carolina, which have higher rates of anaphylactic reactions.
The American Association for Cancer Research (AACR) is honoring world-class cancer researchers for their significant contributions to the fight against cancer. The AACR Awards Program recognizes outstanding achievements in basic cancer research, clinical care, therapeutics, and prevention.
Treatment with letrozole initiated one to seven years after stopping tamoxifen therapy cuts the risk of breast cancer recurrence in half and metastasis by 60%. The chance that a new tumor develops in the unaffected breast is also significantly reduced. These findings suggest aromatase inhibition can still offer preventive benefits.
A new study has demonstrated a lower risk of cardiac toxicity with dose-dense chemotherapy in early-stage HER2-positive breast cancer patients. The regimen, which administers standard doses of chemotherapy agents more frequently, pairs safely with trastuzumab and resulted in only 1.4% cardiac events after 28 months of follow-up.
A novel brain cancer drug showed promising results in mice but caused permanent bone damage in younger animals. The study raises concerns about using similar drugs to treat children's cancers until further understanding of possible risks is gained.
A study found that efficient primary care can prevent over 50% of hospitalizations caused by diabetic ketoacidosis, digestive haemorrhage, and chronic bronchitis in older patients. Effective management of these conditions could also reduce the risk of hospitalization for other health problems.
A combination of two platelet inhibitors, aspirin and APT102, reduced bone tumors in laboratory mice with breast or melanoma cancer. The drugs work by blocking platelets' ability to clot and aid tumor cells, slowing down metastasis.
Researchers have identified 18 plants with substantial anti-cancer properties, including Rangoon Creeper and Red-Root Sage, which outperform conventional treatments against specific tumor cell lines.
Researchers at the University of Michigan have designed a small molecule that activates the p53 protein to kill tumor cells without causing damage to normal cells. The new drug, MI-219, is highly effective in cell cultures and appears safe for use in animals.
A new study, ALTTO, is testing two targeted medications to treat aggressive breast cancer in 8,000 participants across 50 countries. The trial will compare four different regimens of targeted therapy and provide insights into individualized patient care.
Differences in gene expression levels between people of European and African ancestry can impact how they respond to certain drugs. The study found significant differences in several unrelated processes, including genes involved in producing antibodies to microbial invaders.
A Weill Cornell team discovered that EP2 and EP4 receptors play a key role in boosting estrogen production in fat and breast cancer cells. This pathway increases the risk of hormone receptor-positive breast cancer. The study's findings suggest new targets for pharmaceutical research, including drugs that target these receptors.
A University of Minnesota study has shown promising results for thalidomide as a treatment for recurrent ovarian cancer. Patients who received the combination of thalidomide and topotecan had a higher overall response rate and longer cancer-free period compared to those receiving topotecan alone.
Researchers at Fox Chase Cancer Center have discovered that a genetic misalignment can turn a normally quiet developmental gene into a potent driver of T-cell lymphoma in adult mice. The study found that the Dlx5 protein, which is not typically active in healthy adult cells, can be targeted for inhibition to slow cancer growth.
Treating anemia with ESAs increases risk of VTE and death among cancer patients, according to a review of phase 3 trials. There was a significantly increased risk (57") of VTE among patients treated with ESA, while the risk of death was higher for ESA-treated patients compared to the control group.
A Northwestern University study found that cancer patients taking erythropoiesis-stimulating agents (ESAs) have a 10% increased risk of death compared to those who did not take the drugs. The study's findings suggest that ESAs may stimulate the growth of cancer cells, leading to shorter survival rates.
Researchers at Vanderbilt University Medical Center have identified a small protein that specifically recognizes tumors responding to chemotherapy, allowing for rapid visualization of cancer response in mice. This breakthrough could enable more efficient treatment customization and accelerate the development of new cancer drugs.
Researchers are developing new drugs that can modulate male hormone receptors to improve muscle weight without stimulating prostate glands. Studies have shed light on the complex mechanisms behind estrogen receptors in different tissues.
Researchers at NIH have successfully treated a patient with a rare disorder using cancer drug imatinib, which is also effective against systemic mastocytosis and chronic basophilic leukemia. The study's findings offer new treatment options for patients with these complex conditions.
A new clinical trial at Thomas Jefferson University aims to test the effectiveness of radioembolization using radiation-emitting beads in treating advanced liver cancer. The treatment, which blocks blood supply and emits targeted radiation, has shown promise in shrinking tumors and improving patient survival.
The MIT-developed thin-film coating can deliver precise, remote-controlled doses of drugs to specific targets in the body. The film is made from alternating layers of materials and can be activated by applying a small electric field.
A collaborative team of researchers has identified somocystinamide A, a highly potent cancer-fighting compound isolated from cyanobacteria L. Majuscula, which inhibits neovascularization and tumor cell proliferation.
A new study found that 41 false statements appeared on 18 web pages (5.2%) and that websites with complementary or alternative medicine were 15.6 times more likely to have inaccuracies. The authors advise patients to be skeptical of online health information and consult a clinician before taking action.
Researchers at MD Anderson Cancer Center report a new kidney cancer drug that targets the FLT3-ITD mutation in AML, reducing leukemia cells by 90% in patients. The drug has shown minimal side effects and is being tested in combination with chemotherapy.
Researchers found that carbon nanotubes leave the body primarily through the feces, with some by way of the urine. The study also allays worries that the nanotubes would prove toxic to mice, as none died or showed any anomalies in blood chemistry.
A new study funded by the Defense Department aims to develop a drug based on carbon nanotubes to prevent acute radiation injury deaths. The experimental drug, Nanovector Trojan Horses (NTH), has shown promising results in preliminary tests, with mice showing enhanced protection when given first-generation NTH drugs prior to exposure.
A study published in the Journal of Clinical Investigation found that a medication used to treat bone marrow cancer improves bone density in a mouse model of osteoporosis by activating mesenchymal stem cells. This breakthrough could lead to new treatments for osteoporosis and other degenerative conditions.
Researchers create a localized and controlled drug delivery system that is invisible to the immune system, providing a potential solution for cancer and other diseases. The system uses nanoscale polymer films to slowly release anti-inflammatory drugs, reducing side effects and enhancing treatment efficacy.
A systematic review found sorafenib significantly increases the risk of developing hypertension, particularly high-grade hypertension. Patients receiving sorafenib require close monitoring and effective management to prevent cardiovascular complications.
Researchers analyzed data from the National Cancer Institute's Prostate Cancer Prevention Trial, showing that finasteride reduces prostate cancer risk by 25% but also causes side effects like impotence. The study encourages men to consider both benefits and drawbacks before taking the drug to prevent prostate cancer.
A new study published in Nature Genetics reveals that diet and lifestyle can significantly impact the effectiveness of certain drugs, including those used for cancer therapies. The research found that nutrient availability can either enhance or harm cell fitness, depending on the surrounding environment.
Scientists have found a promising anti-cancer drug candidate in HC-toxin, isolated from a fungal maize pathogen. The substance inhibits histone deacetylases, altering genetic material packaging and reducing cancer cell properties.
Researchers at UT Southwestern Medical Center found that hormonal components in over-the-counter dietary supplements can stimulate cancer-cell growth and make anti-cancer drugs less effective. The study's findings highlight the need for patients to inform their doctors about any herbal or hormonal supplements they are taking.
Scientists found that a green glow in fruit flies indicates the activation of cancer-prevention signals similar to those in broccoli and cabbage. The discovery uses Drosophila as a model organism to develop novel approaches for studying the NRF2 pathway, which triggers anti-oxidant activity to fight off toxic assaults.
Dr. Beth Levine, a renowned specialist in autophagy, received the award for medicine for her groundbreaking work that has propelled forward medical research on cancer, Alzheimer's disease, and infectious diseases. Her investigations have identified key genes involved in autophagy, contributing to various diseases.
Researchers found patients taking statins had a lower incidence of cancer compared to non-statin users. Additionally, a new receptor may be targeted for colon cancer treatment, while a mouse model of rare kidney disorder shows promise for studying cancer development.
Researchers developed a novel anticancer strategy targeting PI-3 kinases, which are crucial for cancer cell growth and survival. The compound, SF1126, showed efficacy in seven types of tumors in mice and is being tested in human clinical trials.
Researchers developed a three-drug cocktail targeting glioblastoma multiforme tumors, which showed significant benefits in killing cancer cells and sparing healthy brain tissue. The treatment is based on the first-ever documented molecular signature of GBM tumors and may be tested in patients within five years.
Researchers have identified a key gene, 14-3-3zeta, that enables lung cancer cells to survive on their own. Silencing this gene has been shown to inhibit the growth and survival of lung cancer cells, making it a potential target for selective anti-cancer drugs.
A large clinical trial found that bevacizumab significantly prolongs progression-free survival for women with recurrent breast cancer when combined with chemotherapy. The study showed a doubling of delay in worsening of the disease and improved remission rates compared to chemotherapy alone.
A study published in Journal of Clinical Oncology found that nearly 50% of women over 65 with early stage hormone-positive breast cancer discontinue Tamoxifen treatment before five years. Factors predicting premature discontinuation include age, medical illnesses, and lack of radiation after surgery.
Researchers found that the antimalarial drug chloroquine effectively prevents cancer in mouse models of two human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia. Chloroquine inhibited the development of Myc-induced lymphomas and ATM-deficient mice, but not p53-deficient mice.
Researchers at the University of Pennsylvania have identified that dioxin targets the mitochondria, disrupting normal cellular function and promoting tumor progression. The study's findings suggest that understanding this mechanism could lead to new ways to block the propagation of mitochondrial stress signaling and inhibit cancer growth.
A clinical study at Henry Ford Hospital found that Avastin significantly extended the survival of patients with glioblastoma multiforme, with over half living without disease progression for six months. The use of Avastin also showed no new adverse effects.
A retrospective analysis of sunitinib patients found a risk for heart failure, myocardial infarction, and hypertension. Patients with preexisting coronary artery disease were more likely to develop cardiac problems.
The CTRC-AACR San Antonio Breast Cancer Symposium combines basic, translational, and clinical research to advance breast cancer research. The symposium aims to attract thought-leaders and high-quality papers in basic and translational breast cancer research.
A new 3-drug combination of bortezomib, lenalidomide, and dexamethasone has achieved an impressive overall response rate of 98% in newly diagnosed multiple myeloma patients. The regimen has also shown a high-quality response rate of 52%.
A new test, called RAPID, has been developed to identify proteins that drive cancer growth in acute myeloid leukemia. This breakthrough technology enables researchers to quickly compile a database of mutant genes and potentially match targeted drugs with patients.
Researchers at Oregon Health & Science University Cancer Institute have discovered a new drug candidate, SGX393, effective against highly resistant mutations in CML. Combining SGX393 with existing drugs Sprycel and Tasigna suppresses resistant growth, raising the possibility of 'cocktail' therapies to prevent drug resistance.
A new study published in PLoS Medicine found that consuming high amounts of red and processed meats increases the risk of developing bowel and lung cancer. The research, conducted by Amanda Cross and colleagues, analyzed data from a large US diet and health study involving nearly half a million men and women aged 50-71.
Researchers at Baylor College of Medicine developed a mouse model to study prostate cancer progression, revealing the role of fibroblast growth factor receptor 1 in initiating cancer. The study identified key genes involved in cell plasticity and discovered a new marker for human prostate cancer.
Scientists at Johns Hopkins Medicine discovered that epigenetic changes in gene activation can lead to cancer development, and found a way to block the 'addiction' to growth factors, preventing cancer growth. The study shows that blocking this response can greatly reduce precancerous lesions in animals.
Researchers announced new data showing Gleevec improves outcomes for children with Ph+ ALL, reversing the poor prognosis, and prevents disease progression in adults with CML. Continuous treatment with Gleevec has shown a declining rate of relapse over time, with no patients progressing to advanced phase in CML.
A clinical trial by Mayo Clinic found a lower dose of steroids to be as effective as the standard high-dose treatment in improving overall survival rates for multiple myeloma patients. The new regimen, lenalidomide plus low-dose dexamethasone, showed significantly better results with less toxicity.
Abnormal stem cells with deletions of chromosome 7 or duplications of chromosome 8 have been found in some CML patients, suggesting new targets for therapy. The discovery opens a new window into understanding the roots of chronic myeloid leukemia.